OPK - OPKO Health - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.434B

Cash

110.8M

Avg Qtr Burn

-24.5M

Short % of Float

9.30%

Insider Ownership

46.08%

Institutional Own.

24.25%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rayaldee (calcifediol ER capsules) Details CKD (Chronic kidney disease)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NGENLA® Somatrogon Details Pediatric growth hormone deficiency	NDA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OPK88003 (oxyntomodulin analog) (FLP-1 agonist) Details Type 2 diabetes	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rayaldee Details COVID-19	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.